Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials / 감염과화학요법
Infection and Chemotherapy
;
: 219-224, 2016.
Article
Dans Anglais
| WPRIM
| ID: wpr-28867
ABSTRACT
The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) were analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-naïve and ART-experienced Asian subjects infected with human immunodeficiency virus (HIV)-1. Studies GS-US-236-102 and GS-US-236-103 were randomized, double-blind, placebo-controlled, 144-week studies conducted in ART-naïve subjects, comparing E/C/F/TDF versus efavirenz (EFV)/F/TDF or ritonavir-boosted atazanavir (ATV+RTV) plus emtricitabine/tenofovir DF (F/TDF), respectively. Studies GS-US-236-115 and GS-US-236-121 were randomized, open-label, 96-week long conducted in ART-experienced subjects, who switched to E/C/F/TDF from ritonavir-boosted protease inhibitors (PI+RTV)+F/TDF, or non-nucleoside reverse transcriptase inhibitors (NNRTI)+F/TDF regimens. The E/C/F/TDF appeared to have sustained efficacy and safety and was well tolerated in the small number of ART-naïve and ART-experienced Asian subjects.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Inhibiteurs de protéases
/
VIH-1 (Virus de l'Immunodéficience Humaine de type 1)
/
VIH (Virus de l'Immunodéficience Humaine)
/
Inhibiteurs de la transcriptase inverse
/
Asiatiques
/
Sulfate d'atazanavir
Type d'étude:
Essai clinique contrôlé
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Infection and Chemotherapy
Année:
2016
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS